[1]
Almind, K.; Kahn, C.R. Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes, 2004, 53(12), 3274-3285.
[2]
Browning, J.D.; Szczepaniak, L.S.; Dobbins, R.; Nuremberg, P.; Horton, J.D.; Cohen, J.C.; Grundy, S.M.; Hobbs, H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology, 2004, 40(6), 1387-1395.
[3]
Maher, J.J. New insights from rodent models of fatty liver disease. Antioxid. Redox Signal., 2011, 15(2), 535-550.
[4]
Sanders, F.W.; Griffin, J.L. De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose. Biologic. Rev., 2016, 91(2), 452-468.
[5]
Vacca, M.; Allison, M.; Griffin, J.L.; Vidal-Puig, A. Fatty acid and glucose sensors in hepatic lipid metabolism: Implications in NAFLD. Semin. Liver Dis., 2015, 35(3), 250-261.
[6]
Wree, A.; Broderick, L.; Canbay, A.; Hoffman, H.M.; Feldstein, A.E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol., 2013, 10(11), 627-636.
[7]
Yeh, M.M.; Brunt, E.M. Pathological features of fatty liver disease. Gastroenterology, 2014, 147(4), 754-764.
[8]
Porez, G.; Prawitt, J.; Gross, B.; Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease thematic review series: New lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J. Lipid Res., 2012, 53(9), 1723-1737.
[9]
Ma, Y.Y.; Li, L.; Yu, C.H.; Shen, Z.; Chen, L.H.; Li, Y.M. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J. Gastroenterol., 2013, 19(40), 6911.
[10]
Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Li Volti, G.; Galvano, F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci., 2012, 57(2), 545-553.
[11]
Hong, S.Y.; Oh, J.H.; Lee, I. Simultaneous enrichment of deglycosylated ginsenosides and monacolin K in red ginseng by fermentation with Monascus pilosus. Biosci. Biotechnol. Biochem., 2011, 75(8), 1490-1495.
[12]
Lee, E.J.; Song, M.J.; Kwon, H.S.; Ji, G.E.; Sung, M.K. Oral administration of fermented red ginseng suppressed ovalbumin-induced allergic responses in female BALB/c mice. Phytomedicine, 2012, 19(10), 896-903.
[13]
Reeds, D.N.; Patterson, B.W.; Okunade, A.; Holloszy, J.O.; Polonsky, K.S.; Klein, S. Ginseng and ginsenoside Re do not improve β-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care, 2011, 34(5), 1071-1076.
[14]
Yang, W.S.; Lee, B.H.; Kim, S.H.; Kim, H.G.; Yi, Y.S.; Htwe, K.M.; Kim, Y.D.; Yoon, K.D.; Hong, S.; Lee, W.S.; Cho, J.Y. Dipterocarpus tuberculatus ethanol extract strongly suppresses in vitro macrophage-mediated inflammatory responses and in vivo acute gastritis. J. Ethnopharmacol., 2013, 146(3), 873-880.
[15]
Yang, Y.; Lee, J.; Rhee, M.H.; Yu, T.; Baek, K.S.; Sung, N.Y.; Kim, Y.; Yoon, K.; Kim, J.H.; Kwak, Y.S.; Hong, S.; Kim, J.H.; Cho, J.Y. Molecular mechanism of protopanaxadiol saponin fraction-mediated anti-inflammatory actions. J. Ginseng Res., 2015, 39(1), 61-68.
[16]
Park, H.M.; Kim, S.J.; Mun, A.R.; Go, H.K.; Kim, G.B. KIM, S.Z.; Jang, S.I.; Lee, S.J.; Kim, J.S.; Kang, H.S. Korean red ginseng and its primary ginsenosides inhibit ethanol-induced oxidative injury by suppression of the MAPK pathway in TIB-73 cells. J. Ethnopharmacol., 2012, 141(3), 1071-1076.
[17]
Brunt, E.M.; Janney, C.G.; Di Bisceglie, A.M.; Neuschwander-Tetri, B.A.; Bacon, B.R. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol., 1999, 94(9), 2467.
[18]
Ito, M.; Suzuki, J.; Tsujioka, S.; Sasaki, M.; Gomori, A.; Shirakura, T.; Hirose, H.; Ito, M.; Ishihara, A.; Iwaasa, H.; Kanatani, A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high‐fat diet. Hepatol. Res., 2007, 37(1), 50-57.
[19]
Simon, Y.; Kessler, S.M.; Bohle, R.M.; Haybaeck, J.; Kiemer, A.K. The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut, 2014, 63(5), 861-863.
[20]
Kouakou, K.; Schepetkin, I.A.; Yapi, A.; Kirpotina, L.N.; Jutila, M.A.; Quinn, M.T. Immunomodulatory activity of polysaccharides isolated from Alchornea cordifolia. J. Ethnopharmacol., 2013, 146(1), 232-242.
[21]
Zhao, T.; Mao, G.; Mao, R.; Zou, Y.; Zheng, D.; Feng, W.; Ren, Y.; Wang, W.; Zheng, W.; Song, J.; Chen, Y.; Yang, L.; Wu, X. Antitumor and immunomodulatory activity of a water-soluble low molecular weight polysaccharide from Schisandra chinensis (Turcz.) Baill. Food Chem. Toxicol., 2013, 55, 609-616.
[22]
Miura, K.; Kodama, Y.; Inokuchi, S.; Schnabl, B.; Aoyama, T.; Ohnishi, H.; Olefsky, J.M.; Brenner, D.A.; Seki, E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology, 2010, 139(1), 323-334.
[23]
Nguyen, C.T.; Luong, T.T.; Lee, S.Y.; Kim, G.L.; Kwon, H.; Lee, H.G.; Park, C.K.; Rhee, D.K. Panax ginseng aqueous extract prevents pneumococcal sepsis in vivo by potentiating cell survival and diminishing inflammation. Phytomedicine, 2015, 22(11), 1055-1061.
[24]
Amin, K.A.; Kamel, H.H.; Abd Eltawab, M.A. Protective effect of Garcinia against renal oxidative stress and biomarkers induced by high fat and sucrose diet. Lipids Health Dis., 2011, 10(1), 6.
[25]
Shin, N.R.; Lee, J.C.; Lee, H.Y.; Kim, M.S.; Whon, T.W.; Lee, M.S.; Bae, J.W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut, 2014, 63(5), 727-735.
[26]
Rawson, R.B. The SREBP pathway-insights from Insigs and insects. Nat. Rev. Mol. Cell Biol., 2003, 4(8), 631.
[27]
Wang, Y.; Viscarra, J.; Kim, S.J.; Sul, H.S. Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol., 2015, 16(11), 678.
[28]
Serviddio, G.; Bellanti, F.; Vendemiale, G. Free radical biology for medicine: Learning from nonalcoholic fatty liver disease. Free Radic. Biol. Med., 2013, 65, 952-968.
[29]
Hayakawa, R.; Hayakawa, T.; Takeda, K.; Ichijo, H. Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc. Japan Acad., Series B, 2012, 88(8), 434-453.
[30]
Lawan, A.; Zhang, L.; Gatzke, F.; Min, K.; Jurczak, M.J.; Al-Mutairi, M.; Richter, P.; Camporez, J.P.; Couvillon, A.; Pesta, D.; Roth Flach, R.J.; Shulman, G.I.; Bennett, A.M. Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis. Mol. Cell. Biol., 2015, 35(1), 26-40.
[31]
Bak, E.J.; Choi, K.C.; Jang, S.; Woo, G.H.; Yoon, H.G.; Na, Y.; Yoo, Y.J.; Lee, Y.; Jeong, Y.; Cha, J.H. Licochalcone F alleviates glucose tolerance and chronic inflammation in diet-induced obese mice through Akt and p38 MAPK. Clin. Nutr., 2016, 35(2), 414-421.
[32]
Sun, H.; Wang, X.; Chen, J.; Song, K.; Gusdon, A.M.; Li, L.; Bu, L.; Qu, S. Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice. Lipids Health Dis., 2016, 15(1), 202.
[33]
Alisi, A.; Bedogni, G.; Baviera, G.; Giorgio, V.; Porro, E.; Paris, C.; Giammaria, P.; Reali, L.; Anania, F.; Nobili, V. Randomised clinical trial: The beneficial effects of VSL# 3 in obese children with non‐alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 2014, 39(11), 1276-1285.
[34]
Sepideh, A.; Karim, P.; Hossein, A.; Leila, R.; Hamdollah, M.; Mohammad, E.G.; Mojtaba, S.; Mohammad, S.; Ghader, G.; Seyed Moayed, A. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial. J. Am. Coll. Nutr., 2016, 35(6), 500-505.
[35]
Vitetta, L.; Manuel, R.; Zhou, J.Y.; Linnane, A.W.; Hall, S.; Coulson, S. The overarching influence of the gut microbiome on end-organ function: The role of live probiotic cultures. Pharmaceuticals, 2014, 7(9), 954-989.
68
8